[1]孙燕飞.替诺福韦酯治疗乙型肝炎的效果及对复发率的影响[J].医学信息,2024,37(08):121-124.[doi:10.3969/j.issn.1006-1959.2024.08.024]
　SUN Yan-fei.Effect of Tenofovir Disoproxil in the Treatment of Hepatitis B and its Effect on Recurrence Rate[J].Journal of Medical Information,2024,37(08):121-124.[doi:10.3969/j.issn.1006-1959.2024.08.024]
点击复制

替诺福韦酯治疗乙型肝炎的效果及对复发率的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年08期
页码:
121-124
栏目:
论著
出版日期:
2024-04-15

文章信息/Info

Title:
Effect of Tenofovir Disoproxil in the Treatment of Hepatitis B and its Effect on Recurrence Rate
文章编号:
1006-1959（2024）08-0121-04
作者:
孙燕飞
（安远县人民医院感染科，江西 安远 342199）
Author(s):
SUN Yan-fei
(Department of Infection,Anyuan County People’s Hospital,Anyuan 342199,Jiangxi,China)
关键词:
福韦酯; 乙型肝炎; HBV-DNA转阴率; HBeAg转阴率; 复发率
Keywords:
Tenofovir disoproxil; Hepatitis B; HBV-DNA negative rate; HBeAg negative rate; Recurrence rate
分类号:
R512.6+2
DOI:
10.3969/j.issn.1006-1959.2024.08.024
文献标志码:
A
摘要:
目的 观察替诺福韦酯治疗乙型肝炎的临床效果及对复发率的影响。方法 选取2021年12月-2022年12月我院诊治的72例乙型肝炎患者为研究对象，采用随机数字表法分为对照组和观察组，各组36例。对照组采用恩替卡韦治疗，观察组采用替诺福韦酯治疗，比较两组临床效果、HBV-DNA转阴率、HBeAg转阴率、肝功能指标[丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转氨酶（AST）、总胆红素（TbiL）]、不良反应发生率、复发率。结果 观察组治疗总有效率为94.44%，高于对照组的80.56%（P＜0.05）；观察组HBV-DNA转阴率、HBeAg转阴率均高于对照组（P＜0.05）；两组治疗后ALT、AST、TbiL均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为8.33%，低于对照组的19.44%（P＜0.05）；随访3个月，观察组复发率为11.11%，低于对照组的25.00%（P＜0.05）。结论 替诺福韦酯可提升乙型肝炎患者治疗效果，改善其肝功能，促进HBV-DNA和HBeAg转阴，降低不良反应发生率和复发率，具有较理想的远期临床疗效。
Abstract:
Objective To observe the clinical effect of tenofovir disoproxil in the treatment of hepatitis B and its effect on recurrence rate.Methods A total of 72 patients with hepatitis B diagnosed and treated in our hospital from December 2021 to December 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 36 patients in each group. The control group was treated with entecavir, and the observation group was treated with tenofovir disoproxil. The clinical effect, HBV-DNA negative conversion rate, HBeAg negative conversion rate, liver function index [alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TbiL)], incidence of adverse reactions and recurrence rate were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.44%, which was higher than 80.56% in the control group (P<0.05). The negative conversion rates of HBV-DNA and HBeAg in the observation group were higher than those in the control group (P<0.05). After treatment, ALT, AST and TbiL in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 8.33%, which was lower than 19.44% in the control group (P<0.05). After 3 months of follow-up, the recurrence rate of the observation group was 11.11%, which was lower than 25.00% of the control group (P<0.05).Conclusion Tenofovir disoproxil can improve the therapeutic effect of patients with hepatitis B, improve their liver function, promote the negative conversion of HBV-DNA and HBeAg, reduce the incidence of adverse reactions and recurrence rate, and has ideal long-term clinical efficacy.

参考文献/References:

[1]张岩明,魏子安,何淑英.中西医结合治疗肝胆湿热型慢性乙型肝炎及对免疫功能的影响[J].中华中医药学刊,2018,36(6):1490-1492.[2]徐静,鲍磊,王玉,等.替比夫定联合阿德福韦酯与拉米夫定联合阿德福韦酯治疗慢性乙型肝炎对肾功能影响的对比研究[J].中华肝脏病杂志,2018,26(4):288-293.[3]陈长洋,林志群,李小瑜.替诺福韦酯和恩替卡韦治疗乙型肝炎的效果和用药成本比较[J].中国药房,2018,29(3):397-400.[4]李忠斌,邵清,李梵,等.拉米夫定和阿德福韦酯初始联合与替诺福韦酯单药治疗慢性乙型肝炎48周疗效和安全性比较[J].医学研究杂志,2016,45(4):105-108.[5]Robson M,Im SA,Senkus E,et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J].N Engl J Med,2017,377(6):523-533.[6]杨卫东.苦参碱注射液联合替诺福韦酯治疗拉米夫定耐药慢性乙型肝炎的临床研究[J].现代药物与临床,2018,33(3):582-586.[7]程辉,袁宇慧.不同核苷(酸)类抗病毒药物在失代偿期乙型肝炎肝硬化患者治疗中的应用[J].安徽医药,2016,20(12):2327-2331.[8]中华中医药学会肝胆病专业委员会,中国民族医药学会肝病专业委员会.慢性乙型肝炎中医诊疗指南(2018年版)[J].中西医结合肝病杂志,2019,29(1):1-6.[9]刘蕾,赵鹏,邢雪梅,等.乙型肝炎后肝硬化患者血清AFP-L3、GP-73、CEA与HBV-DNA载量的关系及在肝硬化分级诊断中的价值[J].检验医学与临床,2018,15(3):320-322.[10]陈勇良,李振燕,董春娇,等.FibroTouch联合血清学指标诊断肝纤维化分期相关性分析[J].河北医科大学学报,2019,40(5):607-610.[11]梁志军,李瑞娟,王素娜,等.乙肝肝硬化对外周血T细胞亚群、免疫球蛋白及补体水平的影响[J].陕西医学杂志,2017,46(12):1655-1656.[12]何辉,杨文昊.3种核苷类似物抗病毒药物治疗慢性乙型肝炎不同时间点eGFR对比研究[J].河南医学研究,2017,26(23):4228-4231.[13]张伟伟,赵永芳.富马酸替诺福韦二吡呋酯片联合聚乙二醇化干扰素治疗慢性乙型肝炎疗效观察[J].医学临床研究,2019,36(8):1614-1615.[14]陈川英,陈芳,程全红,等.替诺福韦酯治疗妊娠早期慢性乙型肝炎的效果及对母婴阻断的有效性[J].临床肝胆病杂志,2019,35(7):1493-1495.[15]周昌静,罗杰,崇雨田,等.替诺福韦酯初始单药治疗慢性乙型肝炎患者5年疗效分析[J].中山大学学报(医学科学版),2018,39(5):710-716.[16]邓亮忠,刘晓龙,易云柏,等.富马酸替诺福韦二吡呋酯干预治疗对慢性乙型肝炎患者的疗效及其对肝脏FibroScan值与肝功能的影响[J].抗感染药学,2018,15(8):1468-1469.[17]俞婷婷,常啸,叶英,等.恩替卡韦与阿德福韦酯单药治疗HBeAg阳性慢性乙型肝炎的疗效及安全性[J].江苏医药,2018,44(5):488-490.[18]徐贤丽,劳晓洁,张春兰,等.替诺福韦酯与替比夫定在乙型肝炎病毒母婴阻断中的疗效对比[J].实用医学杂志,2020,36(3):375-379.[19]琚俊科,刘朝阳,李娟,等.替诺福韦酯治疗慢性乙型肝炎的临床疗效及对ALT复常率与HBeAg转阴率的影响[J].慢性病学杂志,2017,18(12):1412-1413,1416.[20]王贺,王千钧,孙风波,等.恩替卡韦联合扶正化瘀胶囊对代偿期慢性乙型肝炎肝硬化患者炎性因子及纤维化指标的影响[J].临床肝胆病杂志,2016,32(9):1734-1738.

相似文献/References:

[1]李安乐,戴 夫,彭 琼.中性粒细胞与淋巴细胞比值、红细胞体积分布宽度与乙型肝炎及乙型肝炎肝硬化的关系研究[J].医学信息,2019,32(03):69.[doi:10.3969/j.issn.1006-1959.2019.03.022]
　LI An-le,DAI Fu,PENG Qiong.Relationship between Neutrophil-lymphocyte Ratio,Red Blood Cell Volume Distribution Width and Hepatitis B and Hepatitis B Cirrhosis[J].Journal of Medical Information,2019,32(08):69.[doi:10.3969/j.issn.1006-1959.2019.03.022]
[2]王媛媛.乙型肝炎患者血清免疫球蛋白检测的意义[J].医学信息,2018,31(18):155.[doi:10.3969/j.issn.1006-1959.2018.18.050]
　WANG Yuan-yuan.Significance of Detection of Serum Immunoglobulin in Patients with Hepatitis B[J].Journal of Medical Information,2018,31(08):155.[doi:10.3969/j.issn.1006-1959.2018.18.050]
[3]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Journal of Medical Information,2018,31(08):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[4]洪 亮,陶 静,张 静,等.上海市男性同性恋HIV感染者中乙型肝炎、丙型肝炎病毒的合并感染情况横断面研究[J].医学信息,2019,32(06):145.[doi:10.3969/j.issn.1006-1959.2019.06.046]
　HONG Liang,TAO Jing,ZHANG Jing,et al.Cross-sectional Study on the Co-infection of Hepatitis B and Hepatitis C Virus among HIV-infected People in Shanghai[J].Journal of Medical Information,2019,32(08):145.[doi:10.3969/j.issn.1006-1959.2019.06.046]
[5]裴金仙,陈天狮,任巧晶,等.IL-23在慢性乙型肝炎免疫调节中的作用研究[J].医学信息,2019,32(08):129.[doi:10.3969/j.issn.1006-1959.2019.08.037]
　PEI Jin-xian,CHEN Tian-shi,REN Qiao-jing,et al.The Role of IL-23 in the Immune Regulation of Chronic Hepatitis B[J].Journal of Medical Information,2019,32(08):129.[doi:10.3969/j.issn.1006-1959.2019.08.037]
[6]方志军.实时荧光PCR检测乙肝病毒DNA的效果评价[J].医学信息,2019,32(22):175.[doi:10.3969/j.issn.1006-1959.2019.22.062]
　FANG Zhi-jun.Evaluation of the Effect of Real-time Fluorescent PCR on Detection of Hepatitis B Virus DNA[J].Journal of Medical Information,2019,32(08):175.[doi:10.3969/j.issn.1006-1959.2019.22.062]
[7]肖岑昕,黄恒青.肠道微生物群与慢性病毒性肝炎的关系[J].医学信息,2021,34(21):39.[doi:10.3969/j.issn.1006-1959.2021.21.009]
　XIAO Cen-xin,HUANG Heng-qing.Relationship Between Intestinal Microflora and Chronic Viral Hepatitis[J].Journal of Medical Information,2021,34(08):39.[doi:10.3969/j.issn.1006-1959.2021.21.009]
[8]李毓龙,刘 琴,黄倩倩.免疫球蛋白检测在乙型肝炎患者的应用价值[J].医学信息,2020,33(13):173.[doi:10.3969/j.issn.1006-1959.2020.13.055]
　LI Yu-long,LIU Qin,HUANG Qian-qian.Application Value of Immunoglobulin Detection in Patients with Hepatitis B[J].Journal of Medical Information,2020,33(08):173.[doi:10.3969/j.issn.1006-1959.2020.13.055]
[9]王明杰,秦玉杰.聚乙二醇干扰素α序贯联合核苷类药物治疗高病毒载量e抗原阳性乙型肝炎的疗效[J].医学信息,2021,34(19):107.[doi:10.3969/j.issn.1006-1959.2021.19.027]
　WANG Ming-jie,QIN Yu-jie.Efficacy of Peginterferon α Sequential Combined with Nucleoside Drugs in theTreatment of High Viral Load e Antigen Positive Hepatitis B[J].Journal of Medical Information,2021,34(08):107.[doi:10.3969/j.issn.1006-1959.2021.19.027]
[10]刘金兰.乙肝两对半和DNA联合检验在乙肝诊断中的价值[J].医学信息,2025,38(08):144.[doi:10.3969/j.issn.1006-1959.2025.08.030]
　LIU Jinlan.Value of Combined Detection of Hepatitis B Virus Serological Markers and DNA in the Diagnosis of Hepatitis B[J].Journal of Medical Information,2025,38(08):144.[doi:10.3969/j.issn.1006-1959.2025.08.030]

更新日期/Last Update: 1900-01-01